Wednesday, November 18, 2020

Chinese COVID vaccine candidate based on inactivated virus appears safe, induces immune response, study finds

Results from an early-phase randomised clinical trial of a Chinese vaccine candidate based on the inactivated whole SARS-CoV-2 virus (CoronaVac) are published today in The Lancet Infectious Diseases journal, finding the formulation appears safe and induces an antibody response in healthy volunteers aged 18 to 59 years.